233 related articles for article (PubMed ID: 25452387)
1. CDK5 is a major regulator of the tumor suppressor DLC1.
Tripathi BK; Qian X; Mertins P; Wang D; Papageorge AG; Carr SA; Lowy DR
J Cell Biol; 2014 Dec; 207(5):627-42. PubMed ID: 25452387
[TBL] [Abstract][Full Text] [Related]
2. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
5. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.
Chen L; Liu C; Ko FC; Xu N; Ng IO; Yam JW; Zhu G
J Biol Chem; 2012 Jul; 287(31):26104-14. PubMed ID: 22645138
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Point Mutations in the
Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
[TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
Cao X; Voss C; Zhao B; Kaneko T; Li SS
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
[TBL] [Abstract][Full Text] [Related]
12. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.
Yang XY; Guan M; Vigil D; Der CJ; Lowy DR; Popescu NC
Oncogene; 2009 Mar; 28(11):1401-9. PubMed ID: 19151751
[TBL] [Abstract][Full Text] [Related]
13. Concerted modulation of paxillin dynamics at focal adhesions by Deleted in Liver Cancer-1 and focal adhesion kinase during early cell spreading.
Kaushik S; Ravi A; Hameed FM; Low BC
Cytoskeleton (Hoboken); 2014 Dec; 71(12):677-94. PubMed ID: 25448629
[TBL] [Abstract][Full Text] [Related]
14. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.
Scholz RP; Regner J; Theil A; Erlmann P; Holeiter G; Jähne R; Schmid S; Hausser A; Olayioye MA
J Cell Sci; 2009 Jan; 122(Pt 1):92-102. PubMed ID: 19066281
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function.
Jensch A; Frey Y; Bitschar K; Weber P; Schmid S; Hausser A; Olayioye MA; Radde NE
J Biol Chem; 2018 Sep; 293(37):14407-14416. PubMed ID: 30045871
[TBL] [Abstract][Full Text] [Related]
16. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
17. LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex.
Zacharchenko T; Qian X; Goult BT; Jethwa D; Almeida TB; Ballestrem C; Critchley DR; Lowy DR; Barsukov IL
Structure; 2016 Jul; 24(7):1130-41. PubMed ID: 27265849
[TBL] [Abstract][Full Text] [Related]
18. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
19. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
20. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.
Zhong D; Zhang J; Yang S; Soh UJ; Buschdorf JP; Zhou YT; Yang D; Low BC
J Cell Sci; 2009 Feb; 122(Pt 3):414-24. PubMed ID: 19158340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
